These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24116862)

  • 1. Treating sickle cell anaemia with hydroxycarbamide.
    Pollack S
    Br J Haematol; 2014 Jan; 164(2):296-7. PubMed ID: 24116862
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroxycarbamide for sickle-cell anaemia in infancy.
    Weatherall DJ
    Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
    [No Abstract]   [Full Text] [Related]  

  • 3. Hydroxycarbamide use in young children with sickle-cell anaemia.
    Obaro SK; Inusa B; Telfer P
    Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098850
    [No Abstract]   [Full Text] [Related]  

  • 4. Hydroxycarbamide use in young children with sickle-cell anaemia.
    Takahashi Y; Mori J; Tsubokura M; Matsumura T; Kami M
    Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098851
    [No Abstract]   [Full Text] [Related]  

  • 5. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxyurea for sickle-cell anaemia in Africa: mind the gap.
    Obaro SK
    Lancet Glob Health; 2015 Mar; 3(3):e124-5. PubMed ID: 25701988
    [No Abstract]   [Full Text] [Related]  

  • 7. The rationale for using hydroxycarbamide in the treatment of sickle cell disease.
    Rees DC
    Haematologica; 2011 Apr; 96(4):488-91. PubMed ID: 21454878
    [No Abstract]   [Full Text] [Related]  

  • 8. The rationale for using hydroxycarbamide in the treatment of sickle cell disease" (Haematologica 2011;96:488-491). Reply.
    Pollack S
    Haematologica; 2011 Jun; 96(6):e30. PubMed ID: 21632838
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxyurea for the treatment of sickle cell anemia.
    Platt OS
    N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
    [No Abstract]   [Full Text] [Related]  

  • 10. Circulating endothelin-3 levels in patients with sickle cell disease during hydroxyurea treatment.
    Makis AC; Hatzimichael EC; Kolios G; Bourantas KL
    Haematologica; 2004 Mar; 89(3):360-1. PubMed ID: 15020278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea and new agents for the treatment of sickle cell disease.
    Rodgers GP
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):713-5. PubMed ID: 16163257
    [No Abstract]   [Full Text] [Related]  

  • 12. [Treatment with hydroxyurea has revolutionized the evolution of sickle cell disease ].
    Bartolucci P; de Montalembert M
    Rev Prat; 2014 Oct; 64(8):1127-8. PubMed ID: 25510141
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment adherence in patients with sickle cell anemia.
    Drotar D
    J Pediatr; 2010 Mar; 156(3):350-1. PubMed ID: 20056235
    [No Abstract]   [Full Text] [Related]  

  • 14. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children.
    Estepp JH; Smeltzer MP; Wang WC; Hoehn ME; Hankins JS; Aygun B
    Br J Haematol; 2013 May; 161(3):402-5. PubMed ID: 23384083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).
    Wang WC; Ware RE; Miller ST; Iyer RV; Casella JF; Minniti CP; Rana S; Thornburg CD; Rogers ZR; Kalpatthi RV; Barredo JC; Brown RC; Sarnaik SA; Howard TH; Wynn LW; Kutlar A; Armstrong FD; Files BA; Goldsmith JC; Waclawiw MA; Huang X; Thompson BW;
    Lancet; 2011 May; 377(9778):1663-72. PubMed ID: 21571150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term use of hydroxyurea for sickle cell anemia.
    Lee DA; Mueller BU
    JAMA; 2003 Aug; 290(6):753-4; author reply 754. PubMed ID: 12915425
    [No Abstract]   [Full Text] [Related]  

  • 18. Hydroxyurea for sickle cell anemia.
    Bachmeyer C; Aractingi S; Lionnet F
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18609755
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients.
    Pallis FR; Conran N; Fertrin KY; Olalla Saad ST; Costa FF; Franco-Penteado CF
    Br J Haematol; 2014 Jan; 164(2):286-95. PubMed ID: 24383847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term use of hydroxyurea for sickle cell anemia.
    Feldman L; Allen S; Westerman M; Feldman L; Gilman-Sachs A; Beaman K
    JAMA; 2003 Aug; 290(6):752-3; author reply 754. PubMed ID: 12915423
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.